

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioner,

v.

ASCLETIS PHARMA CHINA CO. LTD.,
Patent Owner.

Case No. PGR2025-00057
U.S. Patent No. 12,234,236
Title: GLP-1R agonist and therapeutic method thereof

PROPOSED STIPULATED PROTECTIVE ORDER

This standing Protective Order governs the treatment and filing of confidential information, including documents and testimony.

1. Confidential information shall be clearly marked “CONFIDENTIAL INFORMATION” or “HIGHLY CONFIDENTIAL – OUTSIDE ATTORNEYS’ EYES-ONLY INFORMATION.” Information or Items marked “HIGHLY CONFIDENTIAL – OUTSIDE ATTORNEYS’ EYES-ONLY INFORMATION” are extremely sensitive confidential information, disclosure of which to another party or non-party would create a substantial risk of serious harm that could not be avoided by less restrictive means.

2. Access to “CONFIDENTIAL INFORMATION” is limited to the following individuals who have executed the acknowledgment appended to this order:

(A) Parties. Persons who are owners of a patent involved in the proceeding and other persons who are named parties to the proceeding.

(B) Party Representatives. Representatives of record for a party in the proceeding.

(C) Experts. Retained experts of a party in the proceeding who further certify in the Acknowledgement that they are not a competitor to any party, or a consultant for, or employed by, such a competitor with respect to the subject matter of the proceeding.

(D) In-house counsel. In-house counsel of a party.

(E) Support Personnel. Administrative assistants, clerical staff, court reporters and other support personnel of the foregoing persons who are reasonably necessary to assist those persons in the proceeding shall not be required to sign an Acknowledgement, but shall be informed of the terms and requirements of the Protective Order by the person they are supporting who receives confidential information.

(F) The Office. Employees and representatives of the United States Patent and Trademark Office who have a need for access to the confidential information shall have such access without the requirement to sign an Acknowledgement. Such employees and representatives shall include the Director, members of the Board and their clerical staff, other support personnel, court reporters, and other persons acting on behalf of the Office.

3. Access to “HIGHLY CONFIDENTIAL – OUTSIDE ATTORNEYS’ EYES-ONLY INFORMATION” is limited to those persons identified in subsections (B), (C), (E), and (F) of Section 2 above.

4. Employees (e.g., corporate officers), consultants, or other persons performing work for a party, other than those persons identified above in (2)(A)–(E), shall be extended access to confidential information only upon agreement of the

parties or by order of the Board upon a motion brought by the party seeking to disclose confidential information to that person and after signing the Acknowledgment. The party opposing disclosure to that person shall have the burden of proving that such person should be restricted from access to confidential information.

5. Persons receiving confidential information shall use reasonable efforts to maintain the confidentiality of the information, including:

- (A) Maintaining such information in a secure location to which persons not authorized to receive the information shall not have access;
- (B) Otherwise using reasonable efforts to maintain the confidentiality of the information, which efforts shall be no less rigorous than those the recipient uses to maintain the confidentiality of information not received from the disclosing party;
- (C) Ensuring that support personnel of the recipient who have access to the confidential information understand and abide by the obligation to maintain the confidentiality of information received that is designated as confidential; and
- (D) Limiting the copying of confidential information to a reasonable number of copies needed for conduct of the proceeding and maintaining a record of the locations of such copies.

6. Persons receiving confidential information shall use the following procedures to maintain the confidentiality of the information:

(A) Documents and Information Filed With the Board.

(i) A party may file documents or information with the Board along with a Motion to Seal. The Motion to Seal should provide a non-confidential description of the nature of the confidential information that is under seal, and set forth the reasons why the information is confidential and should not be made available to the public. A party may challenge the confidentiality of the information by opposing the Motion to Seal. The documents or information shall remain under seal unless the Board determines that some or all of it does not qualify for confidential treatment.

(ii) Where confidentiality is alleged as to some but not all of the information submitted to the Board, the submitting party shall file confidential and non-confidential versions of its submission, together with a Motion to Seal the confidential version setting forth the reasons why the information redacted from the non-confidential version is confidential and should not be made available to the public. A party may challenge the

confidentiality of the information by opposing the Motion to Seal. The non-confidential version of the submission shall clearly indicate the locations of information that has been redacted. The confidential version of the submission shall be filed under seal. The redacted information shall remain under seal unless the Board determines that some or all of the redacted information does not qualify for confidential treatment.

7. Any person providing testimony in a proceeding may, on the record during the testimony, preliminarily designate the entirety of the person's testimony and all transcriptions thereof as "CONFIDENTIAL INFORMATION" or "HIGHLY CONFIDENTIAL – OUTSIDE ATTORNEYS' EYES-ONLY INFORMATION," pending further review. Within ten days of the receipt of the transcript of the testimony, that person, or that person's representative, shall advise the opposing party of those portions of the testimony to which a claim of confidentiality is to be maintained, and the reasons in support of that claim. Such portions shall be treated as confidential and maintained under seal in any filings to the Board unless, upon motion of a party, the Board determines that some or all of the redacted information does not qualify for confidential treatment.

8. Within 60 days after the final disposition of this action, including the exhaustion of all appeals and motions, each party receiving confidential

information must return, or certify the destruction of, all copies of the confidential information to the producing party. A Party Representative may retain a single copy of the confidential information solely for record-keeping purposes, subject to the provisions of this standing Protective Order.

9. Standard Acknowledgement of Protective Order. The following form may be used to acknowledge the Protective Order and gain access to information covered by this Protective Order.

10. Petitioner Conjupro Biotherapeutics, Inc. and Patent Owner Ascleitis Pharma China Co. Ltd. certify that they accept and agree to the terms of this Protective Order.

Dated: May 7, 2026

BY: /Luke Toft/
Jin Zhu, Ph.D. (Reg. No. 62,869)
Joe G. Chen, Ph.D. (Reg. No. 70,066)
FOX ROTHSCCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
Tel: (609) 895-6297
Fax: (609) 896-1469

Luke Toft (Reg. No. 75,311)
FOX ROTHSCCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
Tel: (612) 607-7336
Fax: (612) 607-7100

Counsel for Petitioner

By: /Geoffrey D. Biegler/
W. Chad Shear (Reg. No. 47,938)
Geoffrey D. Biegler (pro hac vice)
Isha Agarwal (pro hac vice)
Tae Yeon Kim (pro hac vice)
COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

Counsel for Patent Owner

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioner,

v.

ASCLETIS PHARMA CHINA CO. LTD.,
Patent Owner.

Case No. PGR2025-00057
U.S. Patent No. 12,234,236
Title: GLP-1R agonist and therapeutic method thereof

**STANDARD ACKNOWLEDGMENT FOR ACCESS
TO PROTECTIVE ORDER MATERIAL**

I, _____, affirm that I have read and understand the Protective Order; that I will abide by its terms; that I will use the confidential information only in connection with this proceeding and for no other purpose; that I will only allow access to support staff who are reasonably necessary to assist me in this proceeding; that prior to any disclosure to such support staff I informed or will inform them of the requirements of the Protective Order; that I am personally responsible for the requirements of the terms of the Protective Order; and that I agree to submit to the jurisdiction of the Office and the United States District Court for the Eastern District of Virginia for purposes of enforcing the terms of the Protective Order and providing remedies for its breach.

Signed _____